title: Targeting translation: eIF4E as an emerging anticancer drug target.
abstract: The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.
authors.affiliation: College of Life Sciences,Anhui Normal University,Key Laboratory of Biotic Environment and Ecological Safety in Anhui Province,Wuhu 241000,Anhui,China.
authors.forename: Chunwan
authors.initials: C
authors.lastname: Lu
authors.affiliation: Cancer Center,Medical College of Georgia,Georgia Regents University,Augusta,GA 30912,USA.
authors.forename: Levi
authors.initials: L
authors.lastname: Makala
authors.affiliation: Cancer Center,Medical College of Georgia,Georgia Regents University,Augusta,GA 30912,USA.
authors.forename: Daqing
authors.initials: D
authors.lastname: Wu
authors.affiliation: College of Life Sciences,Anhui Normal University,Key Laboratory of Biotic Environment and Ecological Safety in Anhui Province,Wuhu 241000,Anhui,China.
authors.forename: Yafei
authors.initials: Y
authors.lastname: Cai
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D004852:Epoxy Compounds / Q000627:therapeutic use; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism; D018942:Macrolides / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000378:metabolism; D014176:Protein Biosynthesis; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D012254:Ribavirin / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000627:therapeutic use; D000077022:Survivin; D013844:Thiazoles / Q000627:therapeutic use; D014315:Triterpenes / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D001572:Benzofurans
chemical_list: D000970:Antineoplastic Agents; D019938:Cyclin D1; D004852:Epoxy Compounds; D039561:Eukaryotic Initiation Factor-4E; D051034:Inhibitor of Apoptosis Proteins; D018942:Macrolides; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; D012254:Ribavirin; D020123:Sirolimus; D000077022:Survivin; D013844:Thiazoles; D014315:Triterpenes; D042461:Vascular Endothelial Growth Factor A; C107489:BIRC5 protein, human; C467484:VEGFA protein, human; C421324:pateamine A; C489897:silvestrol; D001572:Benzofurans